Table 1 Descriptive characteristics of HIV-infected adults on antiretroviral therapy by mortality and LTFU outcomes
| Â | Mortality | LTFU | ||||||
|---|---|---|---|---|---|---|---|---|
6 months | 12 months | 24 months | 36 months | 6 months | 12 months | 24 months | 36 months | |
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
Gender | ||||||||
 Female (n = 16182) | 304 (54.7) | 395 (55.2) | 519 (56.2) | 576 (56.1) | 1549 (63.2) | 2272 (64.7) | 3358 (65.6) | 4282 (65.9) |
 Male (n = 7708) | 252 (45.3) | 320 (44.8) | 405 (43.8) | 451 (43.9) | 902 (36.8) | 1241 (35.3) | 1759 (34.4) | 2217 (34.1) |
 Total (n = 23890) |  |  |  |  |  |  |  |  |
Age | ||||||||
 20–35 (n = 10827) | 229 (41.2) | 281 (39.3) | 370 (40.0) | 414 (40.3) | 1203 (49.1) | 1797 (51.2) | 2675 (52.3) | 3369 (51.8) |
 36–50 (n = 10629) | 255 (45.9) | 336 (47.0) | 425 (46.0) | 470 (45.8) | 1016 (41.5) | 1404 (40.0) | 2001 (39.1) | 2558 (39.4) |
 51+ (n = 2434) | 72 (12.9) | 98 (13.7) | 129 (14.0) | 143 (13.9) | 232 (9.5) | 312 (8.9) | 441 (8.6) | 572 (8.8) |
 Total (n = 23890) |  |  |  |  |  |  |  |  |
Marital Status | ||||||||
 Divorced (n = 3923) | 91 (17.7) | 126 (19.0) | 165 (19.1) | 178 (18.8) | 451 (21.0) | 644 (20.6) | 906 (19.7) | 1193 (20.3) |
 Married (n = 11143) | 203 (39.6) | 273 (41.1) | 353 (41.0) | 385 (40.7) | 963 (44.7) | 1422 (45.5) | 2128 (46.4) | 2738 (46.7) |
 Single (n = 4091) | 146 (28.5) | 179 (27.0) | 224 (26.0) | 251 (26.5) | 487 (22.6) | 699 (22.4) | 1014 (22.1) | 1235 (21.1) |
 Widowed (n = 2975) | 73 (14.2) | 86 (13.0) | 120 (13.9) | 133 (14.0) | 251 (11.7) | 359 (11.5) | 541 (11.8) | 698 (11.9) |
 Total (n = 22132) |  |  |  |  |  |  |  |  |
BMI | ||||||||
 < 18.5 (n = 3466) | 123 (49.2) | 148 (47.6) | 191 (46.8) | 210 (47.1) | 326 (40.3) | 441 (36.7) | 633 (33.0) | 819 (30.9) |
 18.5–24.9 (n = 6887) | 110 (44.0) | 137 (44.1) | 181 (44.4) | 197 (44.2) | 399 (49.4) | 623 (51.9) | 1027 (53.6) | 1437 (54.3) |
 25–29.9 (n = 1708) | 13 (5.2) | 19 (6.1) | 26 (6.4) | 29 (6.5) | 59 (7.3) | 96 (8) | 178 (9.3) | 264 (10.0) |
 30+ (n = 807) | 4 (1.6) | 7 (2.3) | 10 (2.5) | 10 (2.2) | 24 (3.0) | 41 (3.4) | 79 (4.1) | 128 (4.8) |
 Total (n = 12868) |  |  |  |  |  |  |  |  |
Baseline CD4 | ||||||||
 0–250 (n = 15483) | 387 (91.7) | 491 (90.9) | 648 (91.7) | 715 (90.9) | 1615 (86.5) | 2343 (85.9) | 3357 (83.5) | 4275 (83.1) |
 251–500 (n = 3611) | 34 (8.1) | 48 (8.9) | 56 (7.9) | 69 (8.8) | 236 (12.6) | 366 (13.4) | 630 (15.7) | 830 (16.1) |
 Above 500 (n = 124) | 1 (0.2) | 1 (0.2) | 3 (0.4) | 3 (0.4) | 15 (0.8) | 19 (0.7) | 33 (0.8) | 39 (0.8) |
 Total (n = 19218) |  |  |  |  |  |  |  |  |
Regimen started | ||||||||
 ABC-based (n = 370) | 8 (1.4) | 8 (1.1) | 9 (1.0) | 9 (0.9) | 82 (3.3) | 113 (3.2) | 148 (2.9) | 166 (2.6) |
 AZT-based (n = 4465) | 102 (18.3) | 130 (18.2) | 156 (16.9) | 167 (16.3) | 371 (15.1) | 544 (15.5) | 827 (16.2) | 1102 (17.0) |
 D4T-based (n = 12949) | 360 (64.7) | 466 (65.2) | 613 (66.3) | 690 (67.2) | 1556 (63.5) | 2178 (62.0) | 3062 (59.8) | 3728 (57.4) |
 TDF-based (n = 6106) | 86 (15.5) | 111 (15.5) | 146 (15.8) | 161 (15.7) | 442 (18.0) | 678 (19.3) | 1080 (21.1) | 1503 (23.1) |
 Total (n = 23890) |  |  |  |  |  |  |  |  |
WHO clinical stage at ART initiation | ||||||||
 Stage I (n = 3310) | 30 (6.4) | 40 (6.7) | 53 (6.9) | 63 (7.5) | 231 (13.5) | 354 (14.2) | 572 (15.5) | 763 (16.1) |
 Stage II (n = 6800) | 104 (22.3) | 136 (22.6) | 183 (23.8) | 208 (24.7) | 535 (31.4) | 832 (33.4) | 1267 (34.3) | 1661 (34.9) |
 Stage III (n = 7282) | 249 (53.3) | 322 (53.6) | 404 (52.5) | 436 (51.8) | 801 (47.0) | 1132 (45.5) | 1632 (44.1) | 2047 (43.1) |
 Stage IV (n = 994) | 84 (18.0) | 103 (17.1) | 129 (16.8) | 135 (16.0) | 138 (8.1) | 171 (6.9) | 226 (6.1) | 282 (5.9) |
 Total (n = 18386) |  |  |  |  |  |  |  |  |
Dead | 556 (2.3) | 715 (3.0) | 924 (3.9) | 1027 (4.3) | Â | Â | Â | Â |
LTFU | Â | Â | Â | Â | 2451 (10.3) | 3513 (14.7) | 5117 (21.4) | 6499 (27.2) |